Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from ...
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...
BioPharma Dive3d
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
clinicaltrialsarena3d
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
AFP3d
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...
Investor's Business Daily on MSN3d
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...